Nature Reviews Drug Discovery 16, 589–591 (2017)
The text has been changed to reflect that olaparib is the first, rather than the only, approved synthetic lethality-based drug.
Additional information
The online version of the original article can be found at 10.1038/nrd.2017.165
Rights and permissions
About this article
Cite this article
Mullard, A. Erratum: Synthetic lethality screens point the way to new cancer drug targets. Nat Rev Drug Discov 16, 736 (2017). https://doi.org/10.1038/nrd.2017.190
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.190